Friday, July 10, 2026

pharma · Advanced Solid Tumors · Agitation Associated with Alzheimer’s Disease

Bristol-Myers Squibb Australia

Bristol-Myers Squibb Australia is a pharma organization headquartered in Melbourne, AU. Primary therapeutic focus areas include Advanced Solid Tumors, Agitation Associated with Alzheimer’s Disease, BP-I mania or mania wi

PO Box 1080, Mount Waverley, Victoria 3149, Australia HQ
6 Employees
TGA registrant Type
Company details
Status
Public
HQ
PO Box 1080, Mount Waverley, Victoria 3149, Australia
Employees
6
Programs
93
Drugs
120
Patents
0
Clinical program

CA111-001

Phase 1 · other · Advanced Malignant Tumors

CA111-001 for Advanced Malignant Tumors is a Phase 1 program (other) at Bristol-Myers Squibb Australia Pty Ltd with 1 ClinicalTrials.gov record(s).

Internal code CA111-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Bristol-Myers Squibb Australia Pty Ltd
Phase
Phase 1
Modality
other
Indication
Advanced Malignant Tumors
Status
active
Trials
1